摘要
鼻炎是一種常見的疾病，依其致病機轉的差異約略可分為過敏性鼻炎及非過敏性鼻炎兩大類。藥物治療的主要目標是控制症狀與減低疾病對日常生活帶來的影響，並改善病患生活品質。在選擇藥物上，應先考慮病人的主訴、疾病的嚴重程度和病程。其次，藥物的療效、副作用、安全性、即時性與可用性等，最後也應將病人現有與過往的治療經驗一併列入考量。過敏性鼻炎的藥物治療，依照用藥途徑大致可以分為口服及鼻內局部使用兩大類。口服藥物包括H1型抗組織胺（包括第一代及第二代）、去充血劑、類固醇、白三烯素受體拮抗劑等；局部用藥包括類固醇、H1型抗組織胺、去充血劑、肥大細胞穩定劑、抗膽鹼等鼻噴劑。新型的合併類固醇與抗組織胺鼻噴劑已證實有效適用於中度至重度之過敏性鼻炎病人。我們應對藥物的機轉、使用途徑、劑量、副作用及可能的合併療法有充分認識，才能提供病患最好的個人化醫療並帶來最大的福祉。
並列摘要
Rhinitis is a global disease. Based on the differences in its pathogenesis, it is classified as allergic rhinitis (AR) or non-allergic rhinitis. AR treatment aims to control the disease and eliminate difficulties in everyday life. It depends on (1) patient empowerment and preferences; (2) prominent symptoms, symptom severity, and multimorbidity; (3) efficacy and safety of the treatment; (4) speed of onset of treatment action; (5) current treatment; (6) historic response to treatment; (7) impact on sleep and work productivity; and (8) self-management strategies and resource use. Classical pharmacotherapies for AR include oral or topical antihistamines, antileukotrienes, corticosteroids, mast cell stabilizers, decongestants, and anticholinergic agents. MP29‐02, a novel topical combination of a nasal corticosteroid (fluticasone propionate) and an intranasal antihistamine (azelastine), has been reported to be effective in improving symptoms of AR, suggesting that fixed combinations of topical agents might be the better choice for AR treatment.